

Title (en)

PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER

Title (de)

PD-1 ALS PRÄDIKTIVER MARKER FÜR KREBSTHERAPIE

Title (fr)

UTILISATION DE PD-1 EN TANT QUE MARQUEUR PRÉDICTIF POUR UNE THÉRAPIE CONTRE LE CANCER

Publication

EP 4149616 A1 20230322 (EN)

Application

EP 21803206 A 20210512

Priority

- SE 2050559 A 20200513
- US 202163169532 P 20210401
- US 2021032080 W 20210512

Abstract (en)

[origin: WO2021231641A1] Provided are embodiments for treating breast cancer comprising obtaining a tissue sample of a tumour from a breast cancer patient, determining an expression level of PD-1 in the sample, determining that the expression level is below a threshold level, providing intensified treatment to the subject. The intensified treatment can be intensified radiotherapy treatment.

IPC 8 full level

A61N 5/00 (2006.01); **A61N 5/10** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **G01N 33/574** (2006.01)

CPC (source: EP US)

A61P 35/00 (2018.01 - EP); **A61P 35/04** (2018.01 - EP); **C12Q 1/6886** (2013.01 - EP); **G01N 33/57415** (2013.01 - EP US); **A61N 5/10** (2013.01 - EP); **C12Q 2600/106** (2013.01 - EP); **C12Q 2600/158** (2013.01 - EP); **G01N 2333/70532** (2013.01 - EP US); **G01N 2800/52** (2013.01 - EP US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2021231641 A1 20211118; AU 2021272986 A1 20221222; CA 3183417 A1 20211118; EP 4149616 A1 20230322; US 2023375549 A1 20231123

DOCDB simple family (application)

US 2021032080 W 20210512; AU 2021272986 A 20210512; CA 3183417 A 20210512; EP 21803206 A 20210512; US 202117998334 A 20210512